Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Related Articles
Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid
This case report describes a patient with immune checkpoint inhibitor–associated bullous pemphigoid and preexisting anti-BP180–C-terminus antibodies.
Cardiac Arrest During Long-Distance Running Races
This case series and cohort study uses data from the Race Associated Cardiac Event Registry to determine the incidence and outcomes of cardiac arrest during…
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy
This nonrandomized clinical trial investigates the safety, tolerance, and therapeutic potential of N-acetylcysteine in lowering disease-associated biomarkers in patients with hereditary cystatin C amyloid angiopathy.
The Next Wave After Immunotherapy in Cancer Drug Development
This Viewpoint discusses the history of immunotherapy and the future of targeted therapy to treat cancer.
Awake Prone Positioning in Adults With COVID-19
This meta-analysis examines awake prone positioning to treat patients with COVID-19 and acute hypoxemic respiratory failure and its association with increased odds of survival without…
General AI May Revolutionize Neurology—Or It Might Be Bad
This Viewpoint urges neurology stakeholders to consider the potential dangers of the proliferation of artificial intelligence (AI) in neurology, as well as across the wider…
Breast Cancer Outcomes in Transgender and Gender-Diverse Patients in the National Cancer Database
This cohort study examines breast cancer outcomes in transgender and gender-diverse patients compared with cisgender patients, including overall survival and sociodemographic characteristics.
A New Vision for Site-Neutral Policy
This Viewpoint reviews the history of innovation in cataract surgery and site-neutral policies and suggests changes that could propel clinical innovation, reduce costs, and expand…
Regulatory Approval vs Guideline Endorsement of Novel BP-Lowering Treatments
This Viewpoint describes the benefits and barriers of conducting cardiovascular disease outcome trials to provide evidence of effectiveness of novel blood pressure (BP)–lowering therapies in…
Coverage Retention and Plan Switching Following Switches From a Zero- to a Positive-Premium Plan
This cross-sectional study estimates how zero-premium silver plan turnover affected Marketplace coverage in 29 HealthCare.gov states after the implementation of the American Rescue Plan Act.
